Evidence map›Paper›PMID 34797455›Full record

ArticleClinical & experimental metastasis2022

PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8

Chinami Masuda, Mamiko Morinaga, Daiko Wakita, Keigo Yorozu, Mitsue Kurasawa, Masamichi Sugimoto, Osamu Kondoh

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chinami Masuda *Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan.
Mamiko Morinaga *Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan.
Daiko WakitaProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan.
Keigo YorozuProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan.
Mitsue KurasawaProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan.
Masamichi SugimotoProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan. sugimotomsm@chugai-pharm.co.jp.ORCID 0000-0001-5731-3786
Osamu KondohProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd, 200 Kajiwara, Kamakura, 247-8530, Japan.
Chugai Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases are common complication in cancer patients. Immune checkpoint inhibitors show therapeutic benefits also in patients with central nervous system (CNS) metastases. However, their antitumor effects on metastatic tumors and their underlying mechanisms are still poorly understood. In this study we investigated the antitumor effect of anti-programmed death-ligand 1 (PD-L1) antibody on metastatic brain tumors and evaluated immune responses during treatment. We employed a hematogenous brain metastasis xenograft model using immunodeficient mice with murine lymphocyte infusions. A human non-small-cell lung cancer (NSCLC) cell line stably expressing NanoLuc

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesCell Line, TumorHumansLuciferasesLymphocytesMiceMice, SCIDB7-H1 AntigenLuciferasesnanolucAnti-PD-L1 antibodyCD8+ T cellHematogenous brain metastasis modelLuciferase reporterNon-small-cell lung cancer

Identifiers

PMID34797455
PMCPMC8971192
OpenAlexW3213762896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.